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Abstract 
Aims: The study aimed to launch a T2DM adult cohort that is representative of Hungary 
through a cross-sectional study, to produce the most important quality indicators for T2DM 
care, to describe social inequalities, and to estimate the absolute number of T2DM adult 
patients with uncontrolled HbA1c levels in Hungary. 
Methods: A representative sample of the Hungarian T2DM adults (N=1280) was selected in 
2016. GPs collected data on socio-demographic status by questionnaire, and on history and 
laboratory parameters from medical records. The process and outcome indicators used in the 
international monitoring practice were calculated. The socio-economic status influence was 
determined by multivariate logistic regression models. 
Results: Target achievement was 61.66%, 53.48%, and 54.00% for HbA1c, LDL-C, and 
blood pressure, respectively, in the studied sample (N=1176). In Hungary, 294,534 patients 
have above target HbA1c value out of 495,801 T2DM adults. The education-dependent 
positive association with majority of process indicators was not reflected in HbA1c, LDL-C, 
and blood pressure target achievements. The risk of microvascular complications and 
requirement of insulin treatment were higher among less educated. 
Conclusions: According to our observations, the education-independent target achievement 
for HbA1c and LDL-C is similar as, for blood pressure is less effective in Hungary than in 
Europe. 
Abbreviations:  
T2DM, type 2 diabetes, T1DM, type 1 diabetes, GPMSSP, General Practitioners’ Morbidity 
Sentinel Stations Program, OR, odds ratio, 95%CI, 95% confidence interval, EUBIROD, 
EUropean Best Information through Regional Outcomes in Diabetes, NIHIFM, National 
Institute of Health Insurance Fund Management, TC, total cholesterol, TG, triglyceride, LDL-
C, LDL-cholesterol, HDL-C, HDL-cholesterol, GP, general practitioner, AMI, acute 
myocardial infraction, IHD, ischaemic heart disease, BMI, body mass index, HbA1c, 
haemoglobin A1c, eGFR, estimated glomerular filtration rate 
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1. Introduction 
 
According to the latest estimations,  globally, more than 425 million adults had diabetes in 
2017 [1]. T2DM was the 11
th
 leading cause of burden of disease in 2015 [2]. The health and 
economic burden of T2DM could mainly be described by its complications which are 
considered largely preventable [3]. Early diagnosis and adequate glycaemic control are 
essential for preventing and postponing T2DM complications [4,5]. Although, knowledge has 
been growing on the optimization of T2DM patient care, its translation into daily practice is 
far from acceptable as it is shown by the recent publications on the therapeutic target 
achievements [6]. 
Reflecting the importance of multidisciplinary T2DM care, international organizations have 
released recommendations for T2DM monitoring systems. Despite their heterogeneity, the 
main conception and key indicators have significant overlap [6–8]. Minority of the European 
countries (5 of 47) has well operating diabetes registry. The lack of reliable monitoring 
systems is among the factors, which contribute to the weak guideline adherence [9]. 
Hungary belongs to the group of countries without a well-functioning T2DM care monitoring. 
However (a) there is a type 1 diabetes (T1DM) monitoring system in Hungary (Hungarian 
Childhood Diabetes Registry), which covers the entire country with its obligatory reporting 
system contributing to better-than-European-average long term outcome among children 
[10,11], and (b) national and international surveys were implemented in Hungary. Recent 
surveys were not able to produce data representing of the country: 
 In the DEPAC multinational survey in 2005, endocrinologists or diabetologists completed 
questionnaires for the group of T2DM patients who were treated in secondary care settings. 
The sampling could not cover the T2DM patients who were cared by general practitioners 
[12]. 
 A primary health care-based national cross-sectional study was implemented in 2006, 
which aimed to determine the metabolic disorders’ epidemiologic properties. The sampling 
frame was broader than patients with T2DM [13]. 
 Another primary care-based survey was performed in 2008, which was focused on T2DM 
older than 50 years of age [5,14]. The results from this survey had been used in the EUropean 
Best Information through Regional Outcomes in Diabetes (EUBIROD) international 
collaboration as well [15].  
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The Hungarian Diabetes Association regularly publishes guidelines. Although, these 
guidelines defines the necessary indicators for quality monitoring according to the 
international guidelines [16], the proposed indicators are not applied in practice. 
The only regular, nationwide T2DM care monitoring in Hungary is maintained by the 
National Institute of Health Insurance Fund Management (NIHIFM). Two process indicators 
(the proportion of T2DM patients with HbA1c evaluation and ophthalmological examination 
in the past 12 months) to evaluate GPs’ performance are applied. Their use is not completed 
with application of outcome indicators. This approach is potentially counter-productive in 
terms of the quality development because it establishes the interest of service providers in 
increasing the episode numbers without improving the outcomes [14,17,18]. 
Altogether, Hungarian T2DM adult care quality has not properly been evaluated yet. The 
heterogeneity of the performance has not been assessed, even though it is well demonstrated 
that the poor care quality in certain demographic strata can be responsible for the low 
effectiveness observed in general population. [19–22] Neither surveys nor continuous 
monitoring could produce representative data. 
According to the Non-communicable Diseases Risk Factor Collaboration’s latest estimations, 
the probability of achieving the target of halting the rise in diabetes by 2025 compared to its 
2010-level (among adults 18 years and older), if the post-2000 trends continue, is far from 
achievable in Hungary[23]. Therefore, this trend has to be targeted by 
developing/restructuring diabetes care, which is hardly feasible without relying detailed and 
reliable data from representative monitoring. 
The objectives of our study were (1) to launch a national representative T2DM adult cohort 
through a cross-sectional study, ensuring further possibilities for continuous follow-up, (2) to 
produce and evaluate in European context the most important process and outcome quality 
indicators for T2DM care, (3) to describe the social inequalities of these indicators, and (4) to 
estimate the absolute number of T2DM adult patients with uncontrolled HbA1c levels in 
Hungary. 
 
 
3. Materials and Methods 
 
3.1. Setting 
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The General Practitioners’ Morbidity Sentinel Stations Program (GPMSSP) has collected data 
on the occurrence and incidence of diseases, which have major public health importance, as a 
Hungarian surveillance system since 1998. T2DM is among the GPMSSP monitored diseases. 
It has represented the demographical structure and geographical distribution of the Hungarian 
population. The design of this programme has been described in detail elsewhere [24]. 
 
3.2. Study design 
A population-based, nationally representative cohort of (above 18 years old) adult T2DM 
patients was launched in the framework of GPMSSP. A cross-sectional study was performed 
to start the follow-up.  
 
3.3 Participants 
Two-stage sampling was performed. The first step was the random selection of 32 out of the 
total 121 GPMSSP GPs representative of Hungary. The participating GPs prepared their 
T2DM patient lists, which were used as the sampling frame. These were used in the second 
stage of sampling with a random selection of 40 patients in each practice, resulting in a total 
of 1280 subjects. Selected patients had been contacted. Collection of their data had been 
commenced if they had signed the informed consent form. 
 
3.4. Data sources 
GPs registered basic information on the participating patients’ ages, genders, and levels of 
education (classified as primary/secondary/tertiary level). The socio-economic status of the 
patients was approximated by the level of education. The following data on history had been 
derived from patient records where the general routine of GPs’ were used for diagnoses: 
duration of diabetes, complications/comorbidities (stroke, hypertension, IHD, AMI, 
retinopathy, nephropathy, and amputation), application of insulin, antihypertensive and anti-
dyslipidemic drugs, date of the last HbA1c check and eye examination, medication related to 
lipid disorders, hypertension and laboratory investigation. The following laboratory 
parameters had been retrieved from medical records: fasting blood glucose, HbA1c, BMI, 
waist circumference, blood pressure, eGFR, total cholesterol (TC), triglyceride (TG), LDL-
cholesterol (LDL-C), and HDL-cholesterol (HDL-C). The last, a maximum of 12 months 
prior, registered findings used for analysis, which was derived from routine health check 
examinations. Recent guidelines were used to dichotomize parameters. The cut-off values 
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were as follows: 140/85 mmHg for blood pressure, 30 kg/m
2
 for BMI, 102/88 cm 
(male/female) for waist circumference, 1/1.3 mmol/l (male/female) for HDL-C, 2.5 mmol/l 
for LDL-C, 4.5 mmol/l for TC, 1.7 mmol/l for TG and 7.8 mmol/l for fasting blood glucose 
[25]. For HbA1c, we used individualized values based on recent target range 
recommendations [26].  Data collection was performed in 2016. 
3.5 Statistical analysis 
 
Descriptive statistics were created on patient characteristics, on the following process quality 
indicators: proportions of patients who received an annual check for HbA1c, eGFR and lipid 
(TC, LDL-C, HDL-C, TG) status, ophthalmological and physical examination (blood 
pressure, BMI and waist circumference measurements), and on the following outcome 
indicators: whose hypertension and dyslipidaemia had been treated, had controlled fasting 
blood glucose, HbA1c, TC, TG, LDL-C, and HDL-C levels, and had controlled BMI, waist 
circumference, and blood pressure. Proportions of patients with diagnosed complications 
(stroke, hypertension, IHD, AMI, retinopathy, nephropathy, and amputation) and with 
launched insulin therapy have been also computed. 
Proportions were computed with 95% confidence intervals (95%CI). All the descriptive 
indicators have been computed for each levels of education (primary,secondary,tertiary 
respectively) also. The difference between education specific indicators has been tested by 
chi-squared test. 
The observed gender- and age-specific (by 18-44, 45-64, and above 65 years-of-age groups) 
proportions of the HbA1c target achievement, the GPMSSP-derived corresponding T2DM 
prevalence rates, and the population composition of the whole country were used to estimate 
the percentage and number of T2DM patients who reached an HbA1c target in Hungary. 
Weights were applied to correct for the unequal probability of selection and for nonresponse 
as well as to perform post-stratification by age and gender in the survey. The survey analysis 
module of Stata  was used to calculate the 95% confidence intervals of the prevalence 
estimates after considering the sampling design [27]. 
Multivariate logistic regression modelling was used to investigate the influence of socio-
demographic and clinical factors on achievement of quality indicators. The effects of the age, 
gender, level of education, duration of T2DM, requirement of insulin treatment and 
comorbidities on reaching the target HbA1c, fasting blood glucose, BMI, waist 
circumference, blood pressure, TC, TG, LDL-C, and HDL-C and undergoing an annual 
HbA1c check, ophthalmological examination, BMI and waist circumference measurements, 
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and assessment of TC, TG, LDL-C, and HDL-C concentrations, and implementation of 
required antihypertensive and anti-dyslipidaemic treatments were quantified. 
The age, gender, level of education, and duration of T2DM were controlled for in the 
statistical models where comorbidities, complications, and requirement of insulin treatment 
were the dependent variables. The results were described by the odds ratios (OR) and their 
95% confidence intervals. Statistical analysis was performed by Stata (version 10) [28]. 
4. Results 
 
The study response rate was 91.87%. The completed database consisted of 1176 participants. 
(Figure 1) 
 
4.1. Sample characteristics 
 
The female/male ratio was 1.22 (nfemale=647, nmale=529). The mean (±SD) age of diabetes 
patients and average duration of diabetes were 66.52 (±11.12) and 9.76 (±6.73) years in the 
sample. The distribution of patients with education levels was followings: 39.63% with 
primary education, 47.28% with secondary education and 13.10% with tertiary education. 
Insulin therapy, antihypertensive and anti-dyslipidaemic medication were applied in 236 
(20.05%), 1020 (86.66%), and 676 (57.43%) of patients, respectively. 
The highest prevalence among comorbidities was observed for hypertension (87.24%), while 
the lowest prevalence was observed for amputation (0.77%). Stroke (8.16%) and AMI 
(6.38%) were associated with similar proportions, while IHD (33.16%) had a higher 
proportion. Retinopathy and nephropathy affected 180 (15.31%) and 183 (15.56%) 
participants. (Appendix 3) 
 
4.2. Process and outcome indicators 
 
Annual HbA1c check and ophthalmological examination were attended by 1020 and 755 
patients, the attendance rates and 95%CIs were 86.73% [84.80-88.67%] and 64.20% [61.46-
66.94%], respectively. The proportion of patients who participated in physical examination 
and laboratory investigation varied from 57.4 to 100%. The assessment of the LDL-C, eGFR, 
and HDL-C statuses was implemented in less than 80%. (Table 1, Appendix) 
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The mean HbA1c level was 7.06% (±1.35%), which ranged from 4.40 to 13.60%. The 
personalized HbA1c target level was achieved by 398 patients. The overall proportion of 
patients who had an HbA1c above the target value was 61.66% [58.70-64.62%]. The 
proportions of uncontrolled patients for other outcome indicators ranged from 30.8% for 
HDL-C to 87.37% for eGFR. The proportions of patients with LDL-C and blood pressure 
above the therapeutic targets were 53.48% and 54.00%, respectively. (Table 1) 
 
4.3. Population-based estimation 
 
The proportions for reaching the target HbA1c value were calculated in age and gender strata 
using our survey’s data. There was no significant difference between the two genders in 
achieving the target HbA1c level. According to the extrapolation from the surveyed sample to 
the whole adult population of Hungary, the population of T2DM patients in the country 
consisted of 495,801 [431,514-560,089] adults, and the number of T2DM patients in Hungary 
with an HbA1c level that was higher than their personalized target was 294,534 [262,391-
326,678]. (Table 2) 
 
4.4. Education dependence of indicators 
 
Detailed results from analyses on education strata specific indicators are summarized in 
appendix. According to the multivariate models, the higher level (secondary and tertiary) of 
education was a consequent motivating factor for each process indicator apart from the fasting 
blood glucose check-up, and the implementation of antihypertensive and anti-dyslipidaemic 
treatment. This relationship was education level dependent. The utilization of check-ups was 
more intensive among secondary and much more intensive among tertiary than among 
primary level educated patients. (Table 3) 
HbA1c, blood pressure and LDL-C therapeutic target achievements were not associated with 
patients’ education. The higher level of education was a significant protective factor for 
fasting blood glucose and HDL-C target achievements. In contrast, total cholesterol and 
triglyceride control were less likely at goal among patients with higher education. The obesity 
and the central obesity showed no association with the education. (Table 3) 
Most of the long-term outcome indicators showed education independency. Ischemic heart 
diseases and consequently the macrovascular complications were more frequent among highly 
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educated patients. The manifestation of microvascular complications was less likely among 
secondary and the application of insulin treatment among tertiary educated patients. (Table 3) 
 
5. Discussion 
Our study presents nationwide, representative Hungarian data related to T2DM care among 
adults from primary care, covering process and outcome indicators, establishing the required 
baseline data for future follow-up. It describes heterogeneity of care quality in the function of 
the education , and estimates the number of T2DM patient with uncontrolled HbA1c status 
exploiting the opportunities from the representative nature of our study. 
 
5.1. Main findings 
 
5.1.1 Target achievement for intermediate outcome measures 
 
The proportion of those with an HbA1c value below target is similar in Hungary as in other 
Central-Eastern European countries. [12] Approximately 22% achieved the recommended 
target of the 6.5% HbA1c value in the UK. The proportions were 57%, 73%, and 46% in 
Australia, in New Zealand, and the US, where the recommended target HbA1c values were 
under 7%, 8%, and 7%, respectively. [29] Using the 7% cut-off value, recent studies 
(GUIDANCE and PANORAMA) had 53.6% and 62.6% for controlled proportions. 
Achieving the target in Hungary (38.34%), seems to be in the midfield of the reference 
countries. The relative target achievement value (using 2016 Hungarian data as reference) is 
closest to 1 in case of the Australian data from year 2006. (Figure 2) [30–32] 
Related to achieving LDL-C target, Hungary (46.52%) seems to have average proportion of 
controlled ones. (Australia 52.8%, EUROACTION 31.8%). Achievement of the target TC 
level in Hungary (36.29%) is slightly worse compared to other references (US 48%, UK 73%, 
and Australia 44%). The target value achievement is closest to PANORAMA study values 
(2010). [29] 
However, in the respect of blood pressure values the Hungarian achievement seems to be 
significantly weaker (12.16%) than the European references (GUIDANCE 19.3%, 
PANORAMA 19.7% EUROACTION 24.1%). (Figure 2)  
 
5.1.2. Process indicators versus outcome indicators 
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Approximately 83% of T2DM patients attended annual HbA1c check in the UK, 74% in 
Canada, 65% in Australia, 64% in New Zealand and 61% in the US. However, 61% attended 
annual ophthalmological examination in the UK, 48% in Canada, 67% in the US. [29] 
Comparing the attendance rates on annual control examinations with these reference data, 
attendance in Hungary is above the average rate. However, the high quality suggested by 
these process indicators is not reflected in outcome indicators. This observation reassures that 
process indicators only, without outcome indicators, could behave as false quality indicators 
[18,33]. 
 
5.1.3 Socioeconomic gradient 
 
Although, GP own services (treating hypertension and T2DM, checking fasting blood sugar 
level) were not related to patient education, the majority of process indicators which require 
collaboration with secondary care institutions  showed strong and education level dependent 
associations. It was in line with the published results from developed countries [20,21,34]. On 
the other hand, contrary to the recent publications [19,21,35], the better secondary care related 
process indicators are not accompanied with better outcomes. This kind of dissociation was 
observed in Switzerland as well [20]. As it was expected [19], the long-term prognosis seems 
to be better among patients with higher level of education in Hungary as it is shown by the 
less frequent insulin requirement and microvascular complications among them. The 
unexpected association between the higher education and higher occurrence of ischaemic 
heart disease can be explained by the more intensive health checking practice, which leads to 
earlier-stage diagnosis of ischaemic heart diseases. Similar bias was reported by other groups 
also [36]. Because the seriousness of the accompanying disorders was not investigated in our 
survey, this explanation cannot be supported by data, and needs further investigation. 
 
5.2. Strengths and limitations 
 
Our population-based study investigated a representative sample of Hungarian patients with 
T2DM. Because, the sampling frame was the whole list of patients from participating general 
medical practices, and the data collection from medical records was retrospective with 
standardized protocol, GPs could not affect either the sampling or the selection of the clinical 
data. Data on wide range of socio-demographic and clinical factors were collected making 
possible the effective control for confounding. The higher-than-90% response rate contributed 
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to the prevention of selection bias. Because the sample size was comparable with the country 
level subsamples of GUIDANCE and PANORAMA studies, our conclusions rely on similar 
statistical power as the country specific findings of those two reference studies have. [37,38] 
The main validity problem may have been introduced into the study is an overestimation of 
the quality of care. Since GPs from the GPMSSP are volunteers, it can be assumed that 
careful GPs are overrepresented in the survey. According to the NIHIFM data the age and sex 
adjusted relative risk of premature mortality in the investigated group of general medical 
practices compared to the national reference is 1.01 (not deviated significantly from the 
Hungarian average risk), this bias cannot be remarkable. Scarce resources allowed us to focus 
mainly on quality and response rate, however further investigations are planned to expand the 
indicator set and continue the follow-up. 
 
5.3. Conclusions 
 
Our project could establish a cohort of adult T2DM patients with a sample size corresponds to 
the national subsamples of GUIDANCE and PANORAMA studies. The cohort was described 
by process and outcome indicators recommended for monitoring practice, making the 
Hungarian results useful in comparative international analyses, by providing reliable reference 
data. Because the sample is representative for about 500 000 T2DM adults of Hungary, its 
follow-up can monitor the progress in the quality improvement in the care for the cc. 300 000 
patients of the country with missed HbA1c target achievement. 
According to the process indicators, the typical Hungarian care corresponds to or better than 
the reference values from developed countries. The quality of the provided services for 
glycaemic and lipid status control seems to be proper, but the hypertension control needs 
thorough improvement based on the observed target achievements. 
Data on the social inequalities of the key diabetes-related indicators were produced in 
Hungary. The social gradient in service provision could be demonstrated, but this inequality is 
not reflected in the key (HbA1c, LDL-C, and blood pressure) intermediate outcome 
indicators. It seems that the less educated patients reduced access to care provided by 
secondary care institutions, is not converted into intermediate outcome level handicaps. 
However, the long term prognosis does be affected by the social inequality, since the 
proportion of patients requiring insulin therapy, and the prevalence of microvascular 
complications are significantly increased among less educated patients in Hungary. 
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Figure 1 – Patient selection for survey 
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Figure 2 – Relative* HbA1c, blood pressure (BP) and lipid status (LIPID) target value 
achievements in studies compared to the Hungarian (2016) observations 
 
 
* If a threshold applied in a reference study differed from our investigations’ dichotomization 
value in target achievement ascertainment, then our indicator was recalculated according to 
the reference study’s threshold before the ratio of the reference study and the Hungarian 
achievements was calculated. 
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Table 1 - Descriptive characteristics, proportion of patients investigated within 12 months, and with controlled status in the respect of evaluated 
indicators 
 
variables N mean±SD 
proportion of investigated 
patients 
uncontrolled among investigated 
number of patients percentage of patients 
fasting blood glucose (mmol/l) 1127 8.14±2.67 95.83% [94.53-96.9] 509 45.16 [42.25-48.07] 
HbA1c (%) 1038 7.06±1.35 88.27% [86.29-90.05] 640 61.66 [58.70-64.62] 
BMI (kg/m
2
) 1176 
30.68± 
5.13 
100% [99.69-100] 620 52.72 [49.87-55.57] 
waist circumference (cm) 1176 
106.27± 
14.44 
100% [99.69-100] 924 78.57 [76.23-80.92] 
systolic blood pressure (mmHg) 1176 
135.64± 
13.27 
100% [99.69-100] 
635 54.00 [51.15-56.85] 
diastolic blood pressure (mmHg) 1176 
80.62± 
8.08 
100% [99.69-100] 
eGFR (ml/min/1.73m
2
) 942 
69.76± 
17.03 
80.10% [7782-82.38] 823 87.37 [85.25-89.49] 
TC (mmol/l) 1072 5.01±1.23 91.16% [89.39-92.72] 683 63.71 [60.83-66.59] 
TG (mmol/l) 1069 2.01±1.37 90.9% [89.11-92.48] 524 49.02 [46.02-52.02] 
LDL-C (mmol/l) 675 2.76±1.04 57.4% [54.51-60.25] 361 53.48 [49.72-57.24] 
HDL-C (mmol/l) 893 
1.39± 
0..63 
75.94% [73.39-78.35] 275 30.8 [27.77-33.83] 
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Table 2 - Population-based estimations for the number of diabetes patients reaching target HbA1c level stratified by age and gender 
 
 
 
male female 
 
 
18-44 45-64 65-X Total 18-44 45-64 65-X Total 
GPMSSP 
T2DM prevalence 
% (n/N) 
1.04 
(477/ 
45730) 
8.65 
(2914/ 
33677) 
17.07 
(2760/ 
16169) 
6.44 
(6151/ 
95576) 
0.85 
(371/ 
43787) 
6.27 
(2292/ 
36533.5) 
14.9 
(4215/ 
28289) 
6.33 
(6878/ 
108609.5) 
controlled 
HbA1c 
observed in the survey 
% [95% confidence 
interval] 
49.39 
[28.59-70.4] 
46.81 
[38.71-55.08] 
32.22 
[22.68-43.51] 
40.44 
[33.24-48.07] 
31.27 
[12.88-58.32] 
53.74 
[45.21-62.06] 
34.27 
[28.27-40.81] 
40.74 
[35.28-46.43] 
estimation for Hungary 
number of patients [95% 
confidence interval] 
9162 
[5032-13292] 
51416 
[42343-
60489] 
33966 
[22856-
45077] 
94545 
[77076-
112013] 
4628 
[1054-8202] 
47997 
[40403-
55592] 
54097 
[44145-
64049] 
106722 
[92047-
121398] 
uncontrolled 
HbA1c 
observed in the survey 
% [95% confidence 
interval] 
50.61 
[29.6-71.41] 
53.19 
[44.92-61.29] 
67.78 
[56.49-77.32] 
59.56 
[51.93-66.76] 
68.73 
[41.68-87.12] 
46.26 
[37.94-54.79] 
65.73 
[59.19-71.73] 
59.26 
[53.57-64.72] 
estimation for Hungary 
number of patients [95% 
confidence interval] 
9389 
[5258-13519] 
58428 
[49355-
67501] 
71450 
[60340-
82561] 
139267 
[121799-
156736] 
10173 
[6599-13747] 
41317 
[33722-
48911] 
103778 
[93826-
113730] 
155267 
[140592-
169942] 
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Table 3 – Process indicators of type 2 diabetes care (implementation of annual check-ups and 
application of medication for dyslipidaemia and hypertension), occurrence of uncontrolled 
status in the respect of intermediate outcome indicators, comorbidities, and insulin treatment 
requirement by education of patients 
Indicators 
adjusted OR [95% confidence interval] by education 
Secondary/Primary Tertiary/Primary 
Process indicators:   
Ophthalmological check-up* 1.700   [1.276-2.264] 3.018   [1.941-4.694] 
HbA1c check-up* 1.573   [1.076-2.299] 4.936   [2.196-11.097] 
Treated dyslipidaemia* 1.268   [0.957-1.680] 1.123   [0.754-1.672] 
Treated hypertension* 1.362   [0.789-2.351] 1.034   [0.478-2.238] 
Fasting blood glucose check-up* 1.221   [0.640-2.329] 2.220   [0.728-6.764] 
TC check-up* 2.281   [1.435-3.626] 5.036   [1.947-13.027] 
TG check-up* 2.117   [1.343-3.337] 5.271   [2.036-13.647] 
LDL-C check-up* 1.214   [0.928-1.590] 2.127   [1.418-3.191] 
HDL-C check-up* 1.708   [1.258-2.320] 2.731   [1.642-4.543] 
Uncontrolled intermediate outcomes:   
HbA1c* 0.714   [0.451-1.130] 0.714   [0.364-1.400] 
Fasting blood glucose* 0.998   [0.758-1.315] 0.661   [0.442-0.988] 
BMI* 0.802   [0.611-1.053] 0.801   [0.544-1.181] 
Waist circumference* 0.932   [0.658-1.321] 0.874   [0.546-1.401] 
Blood pressure* 1.032   [0.779-1.367] 0.929   [0.618-1.394] 
TC level* 1.341   [0.999-1.800] 1.662   [1.088-2.54] 
TG level* 1.567   [1.181-2.080] 1.441   [0.971-2.141] 
LDL-C level* 1.158   [0.806-1.665] 1.169   [0.722-1.893] 
HDL-C level* 0.676   [0.481-0.950] 0.891   [0.556-1.428] 
Comorbidities and insulin requirement:   
Hypertension** 1.195   [0.800-1.784] 1.485   [0.807-2.734] 
Retinopathy** 0.707   [0.491-1.020] 0.661   [0.380-1.149] 
Stroke** 1.115   [0.684-1.818] 1.131   [0.579-2.209] 
Myocardial infraction** 1.452   [0.846-2.494] 0.614   [0.243-1.554] 
Ischemic heart disease** 1.332   [0.991-1.790] 1.519   [1.005-2.296] 
Nephropathy** 0.814   [0.556-1.193] 0.857   [0.496-1.479] 
Amputation** 1.179   [0.262-5.299] 0.736   [0.076-7.158] 
Microvascular complication** 0.684   [0.506-0.925] 0.685   [0.440-1.064] 
Macrovascular complication** 1.397   [1.046-1.866] 1.537   [1.022-2.311] 
Insulin treatment** 0.773   [0.552-1.083] 0.565   [0.333-0.960] 
* adjusted for age, sex, duration of diabetes, application of insulin treatment, manifestation of 
hypertension, retinopathy, stroke, myocardial infraction, ischemic heart disease, nephropathy, 
amputation by multivariate logistic regression analysis 
** adjusted for age, sex, duration of diabetes by multivariate logistic regression analysis 
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Appendix 1 – Process indicators of type 2 diabetes care (implementation of annual check-ups and application of medication for dyslipidaemia 
and hypertension) by education patients 
Indicators 
Prevalence [95% confidence interval] by education adjusted OR [95% confidence interval] by education* 
Primary Secondary Tertiary Total p-value 
Secondary/Pri
mary 
p-value 
Tertiary/Prima
ry 
p-value 
Ophthalmological 
check-up 
58.37 
[53.89-62.84] 
65.65 
[61.70-69.59] 
76.62 
[69.94-83.31] 
64.20 
[61.46-66.94] 
<0.001 
1.700 
[1.276-2.264] 
<0.001 
3.018 
[1.941-4.694] 
<0.001 
HbA1c check-up 
82.40  [78.95-
85.86] 
87.95 
[85.24-90.66] 
95.45 
[92.16-98.74] 
86.73 
[84.80-88.67] 
<0.001 
1.573 
[1.076-2.299] 
0.019 
4.936 
[2.196-
11.097] 
<0.001 
Treated dyslipidaemia 
56.01 
[51.50-60.52] 
58.99 
[54.90-63.08] 
56.49 
[48.66-64.32] 
57.48 
[54.66-60.31] 
0.608 
1.268 
[0.957-1.680] 
0.099 
1.123 
[0.754-1.672] 
0.57 
Treated hypertension 
87.34 
[84.32-90.36] 
86.15 
[83.28-89.02] 
87.01 
[81.70-92.32] 
86.73 
[84.80-88.67] 
0.855 
1.362 
[0.789-2.351] 
0.268 
1.034 
[0.478-2.238] 
0.932 
Fasting blood glucose 
check-up 
95.71 
[93.87-97.55] 
95.50 
[93.78-97.23] 
97.40 
[94.89-99.91] 
95.83 
[94.69-96.98] 
0.599 
1.221 
[0.640-2.329] 
0.545 
2.220 
[0.728-6.764] 
0.161 
TC check-up 
86.91 
[83.85-89.97] 
93.17 
[91.07-95.26] 
96.75 
[93.95-99.55] 
91.16 
[89.53-92.78] 
<0.001 
2.281 
[1.435-3.626] 
<0.001 
5.036 
[1.947-
13.027] 
0.001 
TG check-up 
86.91 
[83.85-89.97] 
92.63 
[90.45-94.80] 
96.75 
[93.95-99.55] 
90.90 
[89.26-92.55] 
<0.001 
2.117 
[1.343-3.337] 
0.001 
5.271 
[2.036-
13.647] 
0.001 
LDL-C check-up 
54.72 
[50.20-59.24] 
56.29 
[52.17-60.42] 
69.48 
[62.21-76.75] 
57.40 
[54.57-60.22] 
0.004 
1.214 
[0.928-1.590] 
0.158 
2.127 
[1.418-3.191] 
<0.001 
HDL-C check-up 
69.74 
[65.57-73.91] 
78.42 
[75.00-81.84] 
85.71 
[80.19-91.24] 
75.94 
[73.49-78.38] 
<0.001 
1.708 
[1.258-2.320] 
0.001 
2.731 
[1.642-4.543] 
<0.001 
* adjusted for age, sex, duration of diabetes, application of insulin treatment, manifestation of hypertension, retinopathy, stroke, myocardial 
infraction, ischemic heart disease, nephropathy, amputation by multivariate logistic regression analysis 
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Appendix 2 – Occurrence of uncontrolled status in the respect of intermediate outcome indicators among type 2 diabetes patients by education 
Indicators 
Prevalence [95% confidence interval] by education adjusted OR [95% confidence interval] by education* 
Primary Secondary Tertiary Total p-value 
Secondary/Pri
mary 
p-value 
Tertiary/Prima
ry 
p-value 
HbA1c 
64.89 
[60.17-69.60] 
59.24 
[54.92-63.55] 
61.22 
[53.35-69.10] 
61.66 
[58.70-64.61] 
0.226 
0.714 
[0.451-1.130] 
0.151 
0.714 
[0.364-1.400] 
0.327 
Fasting blood glucose 
45.29 
[40.67-49.91] 
47.46 
[43.21-51.70] 
36.67 
[28.95-44.38] 
45.16 
[42.26-48.07] 
0.064 
0.998 
[0.758-1.315] 
0.991 
0.661 
[0.442-0.988] 
0.044 
BMI 
52.36 
[47.83-56.90] 
53.24 
[49.09-57.38] 
51.95 
[44.06-59.84] 
52.72 
[49.87-55.57] 
0.943 
0.802 
[0.611-1.053] 
0.112 
0.801 
[0.544-1.181] 
0.263 
Waist circumference 
82.40 
[78.95-85.86] 
76.80 
[73.29-80.31] 
73.38 
[66.40-80.36] 
78.57 
[76.23-80.92] 
0.023 
0.932 
[0.658-1.321] 
0.693 
0.874 
[0.546-1.401] 
0.576 
Blood pressure 
31.97 
[27.74-36.21] 
35.43 
[31.46-39.41] 
32.47 
[25.07-39.86] 
33.67 
[30.97-36.37] 
0.478 
1.032 
[0.779-1.367] 
0.828 
0.929 
[0.618-1.394] 
0.721 
TC level 
59.26 
[54.47-64.04] 
65.64 
[61.55-69.73] 
69.13 
[61.71-76.55] 
63.71 
[60.83-66.59] 
0.045 
1.341 
[0.999-1.800] 
0.051 
1.662 
[1.088-2.54] 
0.019 
TG level 
41.73 
[36.93-46.53] 
54.17 
[49.87-58.48] 
51.01 
[42.98-59.03] 
49.02 
[46.02-52.01] 
0.001 
1.567 
[1.181-2.080] 
0.002 
1.441 
[0.971-2.141] 
0.07 
LDL-C level 
51.37 
[45.24-57.51] 
54.95 
[49.44-60.46] 
54.21 
[44.77-63.65] 
53.48 
[49.72-57.24] 
0.696 
1.158 
[0.806-1.665] 
0.428 
1.169 
[0.722-1.893] 
0.525 
HDL-C level 
37.85 
[32.57-43.12] 
26.15 
[22.02-30.27] 
28.79 
[21.06-36.51] 
30.80 
[27.77-33.82] 
0.002 
0.676 
[0.481-0.950] 
0.024 
0.891 
[0.556-1.428] 
0.632 
* adjusted for age, sex, duration of diabetes, application of insulin treatment, manifestation of hypertension, retinopathy, stroke, myocardial 
infraction, ischemic heart disease, nephropathy, amputation by multivariate logistic regression analysis 
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Appendix 3 – Comorbidities, complications, and insulin treatment requirement by education among type 2 diabetes patients 
Indicators 
Prevalence [95% confidence interval] by education adjusted OR [95% confidence interval] by education* 
Primary Secondary Tertiary Total p-value 
Secondary/Pri
mary 
p-value 
Tertiary/Prima
ry 
p-value 
Hypertension 
88.41 
[85.51-91.32] 
85.79 
[82.89-88.69] 
88.96 
[84.01-93.91] 
87.24 
[85.34-89.15] 
0.363 
1.195 
[0.800-1.784] 
0.384 
1.485 
[0.807-2.734] 
0.204 
Retinopathy 
19.31 
[15.73-22.90] 
12.77 
[10.00-15.54] 
12.34 
[7.14-17.53] 
15.31 
[13.25-17.36] 
0.008 
0.707 
[0.491-1.020] 
0.064 
0.661 
[0.380-1.149] 
0.142 
Stroke 
8.37 
[5.85-10.88] 
7.73 
[5.51-9.95] 
9.09 
[4.55-13.63] 
8.16 
[6.60-9.73] 
0.833 
1.115 
[0.684-1.818] 
0.662 
1.131 
[0.579-2.209] 
0.719 
Myocardial infraction 
5.58 
[3.50-7.66] 
7.73 
[5.51-9.95] 
3.90 
[0.84-6.95] 
6.38 
[4.98-7.77] 
0.152 
1.452 
[0.846-2.494] 
0.176 
0.614 
[0.243-1.554] 
0.303 
Ischemic heart disease 
33.91 
[29.61-38.20] 
31.29 
[27.44-35.15] 
37.66 
[30.01-45.32] 
33.16 
[30.47-35.85] 
0.299 
1.332 
[0.991-1.790] 
0.057 
1.519 
[1.005-2.296] 
0.047 
Nephropathy 
21.03 
[17.33-24.73] 
11.33 
[8.70-13.97] 
14.29 
[8.76-19.81] 
15.56 
[13.49-17.63] 
<0.001 
0.814 
[0.556-1.193] 
0.291 
0.857 
[0.496-1.479] 
0.579 
Amputation 
0.86 
[0.23-2.18] 
0.72 
[0.20-1.83] 
0.65 
[0.02-3.56] 
0.77 
[0.35-1.45] 
1.000 
1.179 
[0.262-5.299] 
0.83 
0.736 
[0.076-7.158] 
0.792 
Microvascular 
complication 
37.12 
[32.74-41.51] 
22.30 
[18.84-25.76] 
24.68 
[17.87-31.48] 
28.49 
[25.91-31.07] 
<0.001 
0.684 
[0.506-0.925] 
0.014 
0.685 
[0.440-1.064] 
0.092 
Macrovascular 
complication 
38.41 
[34.00-42.83] 
36.69 
[32.68-40.70] 
42.86 
[35.04-50.67] 
38.18 
[35.4-40.96] 
0.378 
1.397 
[1.046-1.866] 
0.024 
1.537 
[1.022-2.311] 
0.039 
Insulin treatment 
22.53 
[18.74-26.33] 
19.42 
[16.14-22.71] 
14.94 
[9.31-20.56] 
20.07 
[17.78-22.36] 
0.111 
0.773 
[0.552-1.083] 
0.135 
0.565 
[0.333-0.960] 
0.035 
* adjusted for age, sex, duration of diabetes by multivariate logistic regression analysis 
 
